CAAS Capital Management’s NKGen Biotech, Inc. Warrants NKGNW Stock Holding History

CAAS Capital Management’s Portfolio NKGNW Stock Details NKGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-10,000	Closed	-$1K	–	583
2024 Q4	$1K	Hold	10,000	–	–	﹤0.01%	356
2024 Q3	$707	Hold	10,000	–	–	﹤0.01%	425
2024 Q2	$870	Hold	10,000	–	–	﹤0.01%	218
2024 Q1	$1.6K	Hold	10,000	–	–	﹤0.01%	493
2023 Q4	$808	Buy	+10,000	New	+$1.35K	﹤0.01%	470
2023 Q3	–	Sell	-10,000	Closed	-$2K	–	841
2023 Q2	$2K	Hold	10,000	–	–	﹤0.01%	649
2023 Q1	$1.4K	Hold	10,000	–	–	﹤0.01%	686
2022 Q4	$849	Hold	10,000	–	–	﹤0.01%	734
2022 Q3	$2K	Hold	10,000	–	–	﹤0.01%	772
2022 Q2	$3K	Hold	10,000	–	–	﹤0.01%	836
2022 Q1	$6K	Hold	10,000	–	–	﹤0.01%	607
2021 Q4	$12K	Buy	+10,000	New	+$10.2K	﹤0.01%	826
2021 Q3	–	Hold	0	–	–	–	908

Other funds holding NKGNW

RCM

Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 19.06% 1-Year Est. Return

CAAS Capital Management's NKGNW Position: Q1 2025 in Review

CAAS Capital Management sold out of NKGen Biotech, Inc. Warrants (NKGNW) in Q1 2025, closing a stake of 10,000 shares — an estimated $1K sold.

CAAS Capital Management first reported a position in NKGNW in Q4 2021 and held it in 12 quarters. The position peaked at $12K in Q4 2021. 3 funds tracked by Wall St. Rank hold NKGNW as of Q1 2025.

CAAS Capital Management reported no remaining NKGen Biotech, Inc. Warrants position as of Q1 2025 after selling out during the quarter.
CAAS Capital Management sold 10,000 NKGen Biotech, Inc. Warrants shares in Q1 2025, an estimated $1K.
CAAS Capital Management first reported a position in NKGen Biotech, Inc. Warrants in Q4 2021 and held it in 12 quarters.
CAAS Capital Management's NKGen Biotech, Inc. Warrants position peaked at $12K in Q4 2021.
3 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Warrants as of Q1 2025.

Based on CAAS Capital Management's 13F filing for Q1 2025, filed 1 May 2025.